PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15549353-1 2004 A proportion of people with multiple sclerosis (MS) treated with interferon (IFN) a develop neutralising anti-IFN beta antibodies (NABs). nabs 131-135 interferon beta 1 Homo sapiens 110-118 15549353-4 2004 In patients treated with IFN beta in whom NABs persist for a significant period of time, their presence is associated with a reduction in both the biological effects and clinical efficacy. nabs 42-46 interferon beta 1 Homo sapiens 25-33 15549353-6 2004 The persistence of NABs appears to be linked to the type of IFN beta treatment as well as the titre of antibodies. nabs 19-23 interferon beta 1 Homo sapiens 60-68 15549353-7 2004 The overall efficacy of IFN beta and, hence, of any biological disease-modifying treatment (DMT) would be substantially improved if the development of NABs could be prevented or reversed. nabs 151-155 interferon beta 1 Homo sapiens 24-32 15549353-10 2004 As a corollary, the therapeutic efficacy of IFN beta could be maximised if patients who tolerate higher-dose preparations could be prevented from developing persistent NABs. nabs 168-172 interferon beta 1 Homo sapiens 44-52 15549353-11 2004 Strategies employed to prevent or reverse the development of NABs with other biological compounds (e. g. insulin, factor VIII, IFN beta, recombinant human erythropoietin) include improvements in the manufacturing process, immunosuppression, induction of tolerance and deimmunisation, and these should be considered in relation to biological DMT therapy as part of future clinical studies. nabs 61-65 interferon beta 1 Homo sapiens 127-135 15045868-1 2004 Patients with multiple sclerosis receiving interferon beta (IFN) may develop neutralizing anti-interferon beta antibodies (NABs). nabs 123-127 interferon beta 1 Homo sapiens 43-58 15045868-4 2004 Differences of immunogenicity between the interferon beta products with regard to their structure, formulation, dose, route of administration were presented and the influence of NABs on the biological and clinical activity of IFN beta therapy was shown. nabs 178-182 interferon beta 1 Homo sapiens 226-234 15045868-1 2004 Patients with multiple sclerosis receiving interferon beta (IFN) may develop neutralizing anti-interferon beta antibodies (NABs). nabs 123-127 interferon beta 1 Homo sapiens 95-110 28293479-1 2017 BACKGROUND: Multiple sclerosis (MS) patients treated with interferon beta (IFNbeta) are at risk of a declining response to treatment because of the production of IFNbeta-neutralizing antibodies (NAbs). nabs 195-199 interferon beta 1 Homo sapiens 58-73 11437159-5 2001 A bioassay was used to detect and quantify the NABs to IFN-beta, measuring the capacity of NABs to block the antiviral resistance induced by IFNs. nabs 47-51 interferon beta 1 Homo sapiens 55-63 28293479-1 2017 BACKGROUND: Multiple sclerosis (MS) patients treated with interferon beta (IFNbeta) are at risk of a declining response to treatment because of the production of IFNbeta-neutralizing antibodies (NAbs). nabs 195-199 interferon beta 1 Homo sapiens 75-82 28293479-1 2017 BACKGROUND: Multiple sclerosis (MS) patients treated with interferon beta (IFNbeta) are at risk of a declining response to treatment because of the production of IFNbeta-neutralizing antibodies (NAbs). nabs 195-199 interferon beta 1 Homo sapiens 162-169 26931196-16 2016 Treatment response to interferon-beta, expressed in relapse rate was independently influenced by gender and the presence of NAbs, but it seems that the presence of NAbs does not affect the treatment effect differently in women and men. nabs 124-128 interferon beta 1 Homo sapiens 22-37 27366230-1 2016 BACKGROUND: Efficacy of interferon beta in multiple sclerosis (MS) can be dampened in patients who develop neutralizing antidrug antibodies (NAbs). nabs 141-145 interferon beta 1 Homo sapiens 24-39 26779831-1 2016 Neutralizing anti-drug antibodies (NAbs) against therapeutic interferon beta (IFNbeta) in people with multiple sclerosis (MS) are measured with cell-based bioassays. nabs 35-39 interferon beta 1 Homo sapiens 61-76 24009164-6 2014 RESULTS: We found that 22 of 164 (13.4%) patients developed NAbs during a median time of 23.8 months on IFN-b treatment. nabs 60-64 interferon beta 1 Homo sapiens 104-109 25208455-6 2014 RESULTS: NAbs significantly abrogated the interferon-beta treatment efficacy in both genders. nabs 9-13 interferon beta 1 Homo sapiens 42-57 24444338-2 2014 The occurrence of neutralizing antidrug antibodies (NAbs) against IFNbeta may reduce treatment response. nabs 52-56 interferon beta 1 Homo sapiens 66-73 24748646-2 2014 Neutralising antibodies against IFNbeta (NAbs) promote a loss of IFNbeta bioactivity in a titre-dependent way and their development was associated with certain human leucocyte antigen (HLA) alleles. nabs 41-45 interferon beta 1 Homo sapiens 32-39 24748646-2 2014 Neutralising antibodies against IFNbeta (NAbs) promote a loss of IFNbeta bioactivity in a titre-dependent way and their development was associated with certain human leucocyte antigen (HLA) alleles. nabs 41-45 interferon beta 1 Homo sapiens 65-72 22976494-7 2012 In total, 5.2% of IFN-beta-1a-treated patients (4/77) and 30.3% of IFN-beta-1b-treated patients (46/152) were positive for Nabs. nabs 123-127 interferon beta 1 Homo sapiens 67-75 24586361-1 2014 BACKGROUND: Anti interferon-beta (IFN-beta) neutralizing antibodies (NAb) affect efficacy of treatment of multiple sclerosis patients, but exactly when the detrimental effects of NAbs offset therapeutic efficacy is debated. nabs 179-183 interferon beta 1 Homo sapiens 34-42 18715196-4 2008 We used microarray analysis and RT-PCR to measure gene expression in whole blood, 9-15 h postinjection, in patients with and without NAbs to IFN-beta. nabs 133-137 interferon beta 1 Homo sapiens 141-149 20610349-3 2010 In June, 2009, a panel of experts in MS and NAbs to interferon-beta therapy convened in Amsterdam, Netherlands, under the auspices of the Neutralizing Antibodies on Interferon beta in Multiple Sclerosis consortium, a European-based project of the 6th Framework Programme of the European Commission, to review and discuss data on NAbs and their practical consequences for the treatment of patients with MS on interferon beta. nabs 44-48 interferon beta 1 Homo sapiens 52-67 18727672-3 2009 METHODS: Data from IFNbeta-treated MS patients who had been tested for NAbs twice (n = 822) were analysed. nabs 71-75 interferon beta 1 Homo sapiens 19-26 17619058-3 2007 Eleven percent of IFNbeta-treated patients showed a lack of MxA induction, with an inverse correlation between MxA mRNA and the presence of BAbs and NAbs. nabs 149-153 interferon beta 1 Homo sapiens 18-25 16241970-11 2005 In patient with NABs, measurements should be repeated, and therapy with IFN-beta should be discontinued in patients with high titres of NABs sustained at repeated measurements with 3- to 6-month intervals (Level A recommendation). nabs 136-140 interferon beta 1 Homo sapiens 72-80 17548434-2 2007 It frequently induces the formation of neutralising anti-Interferon Beta Antibodies (Nabs) which may abrogate the clinical efficacy of the drug. nabs 85-89 interferon beta 1 Homo sapiens 57-72